Company Assembly Biosciences, Inc.

ASMB

US0453962070

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
13.48 ^USD	+1.58%		+4.33%	+36.98%

Mar. 28	Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 19	Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	MT

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Companyâs pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-Î± (IFN-Î±) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

Number of employees: 65

USD in Million	2022	Weight	2023	Weight	Delta
Novel Therapeutics 100.0 %	0	nan %	7	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	nan %	7	100.0 %	-

Managers	Title	Age	Since
Jason Okazaki CEO	Chief Executive Officer	48	20-03-29
Anuj Gaggar CTO	Chief Tech/Sci/R&D Officer	-	Nov. 07
William Delaney CTO	Chief Tech/Sci/R&D Officer	52	20-05-31
John McHutchison BRD	Director/Board Member	66	19-08-05
Shannon Ryan IRC	Investor Relations Contact	-	-
Jeanette Bjorkquist AUD	Comptroller/Controller/Auditor	-	-
John O. Gunderson LAW	General Counsel	-	22-08-31
Nicole White PRN	Corporate Officer/Principal	-	20-11-16
Jennifer A. Troia HRO	Human Resources Officer	-	17-04-30

Members of the board	Title	Age	Since
Susan Mahony BRD	Director/Board Member	60	17-12-13
Gina Consylman BRD	Director/Board Member	52	20-10-19
William Ringo CHM	Chairman	78	14-06-30
Anthony Altig BRD	Director/Board Member	68	11-12-31
Jason Okazaki CEO	Chief Executive Officer	48	20-03-29
Michael Houghton BRD	Director/Board Member	73	21-07-18
John McHutchison BRD	Director/Board Member	66	19-08-05
Tomas Cihlar BRD	Director/Board Member	-	Dec. 06
Lisa Johnson-Pratt BRD	Director/Board Member	60	21-05-19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	5,482,752	3,667,926 ( 66.90 %)	0	66.90 %

Name	Equities	%	Valuation
GILEAD SCIENCES, INC. 19.87 %	1,089,468	19.87 %	14 M $
Alexander Schornstein 12.48 %	684,112	12.48 %	9 M $
Vanguard Global Advisers LLC 3.555 %	194,923	3.555 %	3 M $
Millennium Management LLC 2.204 %	120,837	2.204 %	2 M $
BlackRock Institutional Trust Co. NA 1.342 %	73,597	1.342 %	978 840 $
Anson Funds Management LP 1.094 %	59,956	1.094 %	797 415 $
Geode Capital Management LLC 0.9302 %	51,000	0.9302 %	678 300 $
Renaissance Technologies LLC 0.6543 %	35,876	0.6543 %	477 151 $
Federated MDTA LLC 0.4632 %	25,394	0.4632 %	337 740 $
Acuitas Investments LLC 0.4037 %	22,132	0.4037 %	294 356 $

Assembly Biosciences, Inc.

Two Tower Place 7th floor

94080, South San Francisco

+833 509 4583

http://www.assemblybio.com

address Assembly Biosciences, Inc.(ASMB)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.48 USD

Average target price

36 USD

Spread / Average Target

+167.06%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ASSEMBLY BIOSCIENCES, INC.	+36.98%	73.91M
MERCK KGAA	+4.34%	70.78B
KYOWA KIRIN CO. LTD.	+10.72%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-15.34%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+34.54%	4.22B
YUHAN CORPORATION	+5.09%	3.92B
INDIVIOR PLC	+23.21%	2.55B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.33%	2.24B
BETTA PHARMACEUTICALS CO., LTD.	-24.15%	2.26B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+6.23%	1.92B

Specialty & Advanced Pharmaceuticals